Despite this amount being acknowledged as a limited runway, the recent lifting of the clinical hold on icovamenib, formerly known as BMF-219, and the anticipation of randomized trial data have led to ...

The partnership will leverage Neomorph’s molecular glue discovery platform. Credit: PeopleImages.com – Yuri A/Shutterstock. Biogen and Neomorph have entered a research partnership aimed at discovering ...

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and ...

Announced that World Health Organization (WHO) has approved "icovamenib" as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted ...

Announced that World Health Organization (WHO) has approved“icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States ...

Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 6.1%, or 75c, after results are ...

BOSTON, MA, USA I October 24, 2024 I BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its ...

that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 ...

Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development ...

Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cellsREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- ...